End-of-day quote
Nasdaq
18:00:00 2024-06-24 EDT
|
5-day change
|
1st Jan Change
|
11.82
USD
|
-0.30%
|
|
+0.64%
|
+5.30%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
153.1
|
345.7
|
441.4
|
-
|
-
|
Enterprise Value (EV)
1 |
153.1
|
254
|
313.4
|
416.3
|
448.1
|
P/E ratio
|
-0.72
x
|
-3.18
x
|
-6.24
x
|
-5.53
x
|
-5.27
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
391
x
|
480
x
|
42.2
x
|
13.1
x
|
EV / Revenue
|
-
|
288
x
|
341
x
|
39.8
x
|
13.3
x
|
EV / EBITDA
|
-
|
-3.16
x
|
-5.69
x
|
-11
x
|
59
x
|
EV / FCF
|
-
|
-4,681,856
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
3.69
x
|
3.44
x
|
4.82
x
|
4.5
x
|
Nbr of stocks (in thousands)
|
16,399
|
36,598
|
41,740
|
-
|
-
|
Reference price
2 |
9.336
|
9.445
|
10.58
|
10.58
|
10.58
|
Announcement Date
|
3/28/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.883
|
0.9197
|
10.46
|
33.71
|
EBITDA
1 |
-
|
-80.43
|
-55.06
|
-37.74
|
7.594
|
EBIT
1 |
-
|
-80.71
|
-59.65
|
-61.09
|
-27.88
|
Operating Margin
|
-
|
-9,140.88%
|
-6,485.66%
|
-583.86%
|
-82.71%
|
Earnings before Tax (EBT)
1 |
-
|
-88.7
|
-59.77
|
-68.06
|
-63.96
|
Net income
1 |
-38.7
|
-88.8
|
-61.56
|
-72.08
|
-79.06
|
Net margin
|
-
|
-10,056.85%
|
-6,693.95%
|
-688.85%
|
-234.57%
|
EPS
2 |
-12.94
|
-2.970
|
-1.696
|
-1.911
|
-2.006
|
Free Cash Flow
|
-
|
-54.26
|
-
|
-
|
-
|
FCF margin
|
-
|
-6,144.85%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.25
|
-
|
0.219
|
0.185
|
0.222
|
0.2503
|
0.2451
|
0.2226
|
0.2
|
0.2
|
EBITDA
|
-
|
-
|
-12.89
|
-12.11
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.74
|
-
|
-12.96
|
-12.18
|
-15.33
|
-15.26
|
-15.28
|
-16.07
|
-
|
-
|
Operating Margin
|
-4,298%
|
-
|
-5,917.35%
|
-6,585.95%
|
-6,904.5%
|
-6,098.17%
|
-6,232.87%
|
-7,218.8%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.76
|
-
|
-17.53
|
-12.51
|
-16.06
|
-15.46
|
-15.5
|
-15.53
|
-
|
-
|
Net income
1 |
-12.88
|
-
|
-17.41
|
-12.5
|
-16.09
|
-15.17
|
-15.4
|
-15.88
|
-
|
-
|
Net margin
|
-5,150.8%
|
-
|
-7,951.14%
|
-6,756.22%
|
-7,249.1%
|
-6,062.99%
|
-6,281.18%
|
-7,133.32%
|
-
|
-
|
EPS
2 |
-0.3800
|
-2.530
|
-0.4800
|
-0.3400
|
-0.4400
|
-0.4093
|
-0.4264
|
-0.4435
|
-0.3700
|
-0.3700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/29/23
|
8/29/23
|
11/15/23
|
3/18/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
6.69
|
Net Cash position
1 |
-
|
91.7
|
128
|
25.1
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
0.8805
x
|
Free Cash Flow
|
-
|
-54.3
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-49.1%
|
-
|
6.86%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
2.560
|
3.070
|
2.190
|
2.350
|
Cash Flow per Share
2 |
-
|
-1.800
|
-1.990
|
-2.470
|
-
|
Capex
|
-
|
0.05
|
-
|
-
|
-
|
Capex / Sales
|
-
|
5.44%
|
-
|
-
|
-
|
Announcement Date
|
3/28/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
10.58
CHF Average target price
25.97
CHF Spread / Average Target +145.53% Consensus |
1st Jan change
|
Capi.
|
---|
| +5.30% | 495M | | +38.36% | 52.5B | | +36.73% | 39.31B | | -8.63% | 39.01B | | +25.46% | 28.2B | | -11.17% | 26.57B | | +11.44% | 26.2B | | +45.09% | 14.15B | | +32.93% | 12.62B | | -5.30% | 11.74B |
Other Biotechnology & Medical Research
|